West Pharmaceutical
247 hedge funds and large institutions have $3.65B invested in West Pharmaceutical in 2015 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 76 increasing their positions, 91 reducing their positions, and 14 closing their positions.
612% more call options, than puts
Call options by funds: $2.5M | Put options by funds: $351K
214% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 14
13% more funds holding
Funds holding: 218 → 247 (+29)
0.14% less ownership
Funds ownership: 94.01% → 93.87% (-0.14%)
7% less capital invested
Capital invested by funds: $3.92B → $3.65B (-$276M)
16% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 91
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
Top Sellers
WST Hedge Fund Activity: Q3 2015 in Review
247 of the 3,581 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q3 2015, worth a combined $3.65B — down 7% from $3.92B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new WST positions and 14 closed out — a net gain of 30 holders — while 76 added to existing stakes and 91 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $83M. The largest seller was BlackRock Fund Advisors, cutting an estimated $45M.
- 247 institutional investors held West Pharmaceutical (WST) as of Q3 2015, up from 218 in Q2 2015.
- Funds reported $3.65B of West Pharmaceutical stock for Q3 2015, down 7% quarter-over-quarter.
- 44 funds opened new West Pharmaceutical positions in Q3 2015 and 14 closed out, a net change of +30 holders.
- The largest West Pharmaceutical buyer in Q3 2015 was T. Rowe Price Associates, an estimated $83M added.
- The largest West Pharmaceutical seller in Q3 2015 was BlackRock Fund Advisors, an estimated $45M sold.
Based on aggregated 13F filings for Q3 2015.